Is retatrutide legal in the United States? The answer depends on which rulebook you ask about. FDA approval, pharmacy compounding, controlled-substance law and sport anti-doping rules each treat it differently. This guide takes them one at a time, using FDA statements and warning letters, the DEA list and the WADA list, checked on November 17, 2026.
Quick answer: No pharmacy can fill a prescription for retatrutide or compound it, because it has no FDA approval and FDA says it cannot be compounded. It is not a controlled substance under federal law. Sellers offer it as research material, but FDA decides a product’s intended use from all the evidence, so a “research use only” label does not protect a seller that markets retatrutide for people. Research-grade material is not an alternative to an approved medicine.
This article summarizes public regulatory records. It is not legal advice. For a decision about your own situation, ask a lawyer.
Is retatrutide an FDA-approved drug?
No. FDA states that retatrutide is not a component of any FDA-approved drug and “has not been found safe and effective for any condition” (FDA, 2026). It is an investigational compound in Eli Lilly’s clinical trials, including the Phase 3 trial TRIUMPH-1 (NCT05929066). Our page on retatrutide FDA approval covers the clinical trials and what Lilly has said about timing, so we do not repeat them here.
Can a pharmacy compound retatrutide?
No. FDA’s page on unapproved GLP-1 drugs, current as of October 1, 2026, says plainly: “Retatrutide and cagrilintide cannot be used in compounding under federal law” (FDA, 2026).
FDA set out the reasons in a September 9, 2025 warning letter about compounded retatrutide. A pharmacy compounding under section 503A may use a bulk substance only if it meets one of three conditions. FDA found that retatrutide meets none of them:
- it “is not the subject of an applicable USP or NF monograph”;
- it “is not a component of an FDA-approved human drug”; and
- it “does not appear on the 503A bulks list.”
The same letter found that retatrutide does not appear on the 503B bulks list used by outsourcing facilities either. FDA’s 2026 page adds that it has warned telehealth companies for marketing retatrutide, active ingredient distributors for selling it to compounders, and outsourcing facilities for repackaging it. Our article on the 503A categories explains the wider framework.
Has FDA issued warning letters about retatrutide sold as research material?
Yes. FDA says it has sent warning letters to companies that illegally sold unapproved semaglutide, tirzepatide, retatrutide, survodutide or mazdutide products “falsely labeled” for research purposes or not for human consumption, and that these products were sold directly to consumers for human use (FDA, 2026). Table 1 lists the letters and statements we read.
Retatrutide: FDA actions and status checks
| Date | What happened |
|---|---|
| December 10, 2024 | FDA warning letter to an online seller offering “Retatrutide” labeled “research use only” |
| September 9, 2025 | FDA warning letter finds compounded retatrutide fails the 503A and 503B conditions |
| March 31, 2026 | FDA warning letter over “GLP1-R,” a product FDA identified as retatrutide |
| August 24, 2026 | FDA warning letter over “Retatrutide (GLP-3 RT)” labeled for research use |
| October 1, 2026 | FDA page on unapproved GLP-1 drugs, current as of this date, says retatrutide cannot be compounded |
| November 12, 2026 | DEA controlled substances list edition; retatrutide not listed |
| November 17, 2026 | No FDA approval found |
The research-labeled cases follow one pattern. In the December 2024 letter, the seller’s products carried “RESEARCH USE ONLY” and “INTENDED AS A RESEARCH CHEMICAL ONLY” statements. In the March 2026 letter, the labeling said “laboratory research purposes only” and “not for human consumption, medical use or veterinary use.” In the August 2026 letter, it said “research use only” and “not for human or veterinary use.” Each time, FDA wrote that evidence from the seller’s website established that the products were intended to be drugs for human use. The 2026 letters state that no approved applications are in effect for the products and cite sections 505(a) and 301(d) of the Act, which bar introducing an unapproved new drug into interstate commerce.
Is retatrutide a controlled substance?
Not under federal law. Retatrutide does not appear on the Drug Enforcement Administration’s alphabetical list of controlled substances, edition dated November 12, 2026 (DEA). State laws can differ, and we have not surveyed them. Not being a controlled substance also does not make a product approved or lawful to sell as a drug. That question belongs to FDA.
Is retatrutide banned in sport?
WADA’s 2026 Prohibited List does not name retatrutide. Its S0 section, Non-approved substances, covers any pharmacological substance not addressed elsewhere in the list and “with no current approval by any governmental regulatory health authority for human therapeutic use,” including drugs under clinical development. S0 substances are prohibited at all times. Athletes should check with their anti-doping organization. Our guide to peptides on the 2026 WADA list covers the sections.
What does research-use-only sale mean, and what are its limits?
A “research use only” label states the seller’s intended use: laboratory research, not use in people or animals. Research-grade retatrutide is a laboratory reagent. It is not a medicine and not a substitute for an approved one.
The label has limits. It does not decide the legal question by itself. FDA judges intended use by “objective intent,” which can be shown by labeling claims, advertising, statements and the circumstances in which a product is sold (21 CFR 201.128). When the evidence shows a product is meant for people, FDA can treat it as an unapproved new drug despite the label, as the letters above show. FDA also notes that products sold this way are of unknown quality. A research label says nothing about safety in humans, and FDA states retatrutide has not been found safe and effective for any condition.
Research-grade retatrutide in our catalog is sold for laboratory research use only, not for human or veterinary use. For more, see what research use only means and are peptides legal in the USA.
Frequently asked questions about retatrutide legality
Is retatrutide FDA-approved?
No. FDA states it is not a component of any FDA-approved drug and has not been found safe and effective for any condition.
Can a pharmacy fill a prescription for retatrutide or compound it?
No. There is no approved product to dispense, and FDA states that retatrutide cannot be used in compounding under federal law. Our page on retatrutide FDA approval covers clinical trial access.
Does a “research use only” label make retatrutide legal to sell?
Not by itself. FDA decides intended use from all the evidence, including the seller’s website and marketing. When that evidence showed products were meant for people, FDA treated research-labeled retatrutide as an unapproved new drug.
Is retatrutide a controlled substance?
No. It is not on DEA’s federal list. State law may differ.
Is retatrutide banned by WADA?
The 2026 list does not name it. Its S0 section covers substances with no current approval for human therapeutic use, including drugs in clinical development, and prohibits them at all times.
What to know now
- FDA approval: none; FDA says it has not been found safe and effective for any condition.
- Compounding: FDA states it cannot be used in compounding under federal law; it fails all three 503A conditions.
- Enforcement: FDA warning letters from December 2024 to August 2026 looked past research-use labels.
- Controlled substance: not on DEA’s federal list.
- Sport: not named on the WADA 2026 list; S0 covers non-approved substances.
- Research grade: for laboratory research use only, not for human or veterinary use.
What we’re watching
Any FDA action on an application for retatrutide, which would change every answer on this page; tracked on our retatrutide FDA approval page. New FDA warning letters to sellers. And WADA’s 2027 Prohibited List, which takes effect on January 1, 2027.